Xuantai Pharmaceuticals: Collaborative product Enzalutamide tablets approved by National Medical Products Administration.

Xuantai Pharmaceuticals announced that the Enzalutamide tablets, which the company participated in the development of, have received the "Drug Registration Certificate" issued by the National Medical Products Administration, approving the listing of Enzalutamide tablets. Enzalutamide tablets are suitable for "adult patients with metastatic hormone-sensitive prostate cancer; adult patients with non-metastatic castration-resistant prostate cancer at high risk of metastasis; and adult patients with metastatic castration-resistant prostate cancer who are asymptomatic or have mild symptoms and have not received chemotherapy after failure of androgen-deprivation therapy". According to the agreement between the two parties, the company is responsible for the formulation technology development of the product, and in return will receive sales commissions and technical service fees. The approval of this product is beneficial for further enriching the company's product line, enhancing the company's competitiveness, and positively impacting the company's future business performance.